Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CTSD | P07339 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5366796 | 0.95 | ALDH1A1 (0.41) | ALDH1A1MAPK1GPR35TSHRMEN1 | |
| SCHEMBL5368690 | 0.85 | AKR1C1 (0.49) | ALDH1A1MAPK1GPR35LMNATSHR | |
| SCHEMBL9125609 | 0.81 | ALDH1A1 (0.43) | ALDH1A1MAPK1GPR35MEN1KMT2A | |
| SCHEMBL5369495 | 0.80 | AKR1C1 (0.46) | ALDH1A1MAPK1GPR35TSHRMEN1 | |
| SCHEMBL30937544 | 0.80 | AKR1C1 (0.46) | ALDH1A1MAPK1GPR35TSHRMEN1 | |
| SCHEMBL17241250 | 0.75 | ALDH1A1 (0.47) | ALDH1A1MAPK1GPR35TSHRTDP1 | |
| SCHEMBL30937736 | 0.75 | NPSR1 (0.49) | ALDH1A1MAPK1LMNATSHRMEN1 | |
| SCHEMBL632435 | 0.73 | LMNA (0.43) | ALDH1A1GPR35LMNATSHRMEN1 | |
| SCHEMBL8104865 | 0.73 | HDAC4 (0.44) | LMNAMEN1KMT2ATDP1 | |
| SCHEMBL5369238 | 0.72 | NPSR1 (0.53) | ALDH1A1MAPK1LMNATSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7166616-B2 | Substituted alkanoic acids | AVENTIS PHARMA LIMITED (GB) | 2007-01-23 | — | — | US | disclosed |
| US-20040006056-A1 | For therapy of disease states capable of being modulated by the inhibition of cell adhesion; therapy of asthma | AVENTIS PHARMA LIMITED (GB) | 2004-01-08 | — | — | US | disclosed |
| EP-1330432-A2 | SUBSTITUTED ALKANOIC ACIDS | Aventis Pharma Limited (GB) | 2003-07-30 | — | — | EP | disclosed |
| WO-2002036553-A2 | SUBSTITUTED ALKANOIC ACIDS | AVENTIS PHARMA LIMITED (GB) | 2002-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006056-A1 | For therapy of disease states capable of being modulated by the inhibition of cell adhesion; therapy of asthma | VCAM1, LTB4R, ITGA1 | ALDH1A1 354/4885MAPK1 1073/4885GPR35 647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.